Table 6 BIA analysis results

Iran population

89613176.84

90688534.96

91776797.38

92878118.95

93992656.38

ADHD patients

13979655.59

14147411.45

14317180.39

14488986.56

14662854.39

Market share of methylphenidate

0.27

0.12

0.12

0.10

0.09

Market share of atomoxetine

0.35

0.44

0.43

0.46

0.46

Market share of clonidine

0.39

0.44

0.45

0.44

0.46

Market share of lisdexamfetamine

0.01

0.02

0.03

0.04

0.05

Market share of lisdexamfetamine (IF it is covered by insurance)

0.01

0.03

0.05

0.08

0.11

Scenario 1(without Lisdexamfetamine) ($)

357412

359048

365994

366395

372724

Scenario 2 (with lisdexamfetamine) ($)

368566

421487

430407

433828

443879

Scenario 3 (with lisdexamfetamine and it is covered by insurance) ($)

368566

421483

430,397

433808

443849

Financial impact in scenarios 1&2 ($)

11154

62439

64413

67432

71154

Financial impact in scenarios 1&3 ($)

11154

62434

64403

67412

71124